Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review Article
  • Published:

Epigenetic predictive biomarkers for response or outcome to platinum-based chemotherapy in non-small cell lung cancer, current state-of-art

The Pharmacogenomics Journal volume 19, pages 5–14 (2019)Cite this article

Subjects

Abstract

Platinum-based chemotherapy is commonly used to treat non-small cell lung cancer (NSCLC). However, its efficacy is limited and no molecular biomarkers that predict response are available. In this review, we summarize current knowledge concerning potential epigenetic predictive markers for platinum-based chemotherapy response in NSCLC. A systematic search of PubMed and ClinicalTrials.gov using keywords “non-small cell lung cancer” combined with “chemotherapy predictive biomarkers”, “chemotherapy epigenetics biomarkers”, “chemotherapy microRNA biomarkers”, “chemotherapy DNA methylation” and “chemotherapy miRNA biomarkers” revealed 1740 articles from PubMed and 36 clinical trials. Finally, 22 papers and no trials fulfilled the review criteria. Among miRNA, combination of miR-1290, miR-196b and miR-135a in tumor tissue, and miR-21, miR-25, miR27b, and miR-326 in plasma were predictive for response to platinum-based chemotherapy in advanced NSCLC. RASSF1A methylation measured in tumor or blood was predictive for response to neoadjuvant chemotherapy. These biomarkers remain experimental and none have been tested in a prospective trial.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1

Similar content being viewed by others

References

  1. Pignon J-P,Tribodet H,Scagliotti GV,Douillard J-Y,Shepherd F,Stephens RJ, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol. 2008;26:3552–9.

    Article  Google Scholar 

  2. Burdett S, Jp P, Tierney J, Tribodet H, Stewart L, Le Pechoux C, et al. Adjuvant chemotherapy for resected early-stage non-small cell lung cancer (review). Cochrane Database Syst Rev. 2015;2:CD011430.

  3. Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group. BMJ. 1995;311:899–909.

    Article  Google Scholar 

  4. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002;346:92–8.

    Article  CAS  Google Scholar 

  5. Scagliotti GV, De Marinis F, Rinaldi M, Crinò L, Gridelli C, Ricci S, et al. Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J Clin Oncol Am Soc Clin Oncol. 2002;20:4285–91.

    Article  CAS  Google Scholar 

  6. Butts CA, Ding K, Seymour L, Twumasi-Ankrah P, Graham B, Gandara D, et al. Randomized phase III trial of vinorelbine plus cisplatin compared with observation in completely resected stage IB and II non-small-cell lung cancer: Updated survival analysis of JBR-10. J Clin Oncol. 2010;28:29–34.

    Article  CAS  Google Scholar 

  7. Wallerek S, Sørensen JB. Biomarkers for efficacy of adjuvant chemotherapy following complete resection in NSCLC stages I–IIIA. Eur Respir Rev. 2015;24:340–55.

    Article  Google Scholar 

  8. Felip E, Martinez P. Can sensitivity to cytotoxic chemotherapy be predicted by biomarkers? Ann Oncol. 2012;23:1–4.

    Article  Google Scholar 

  9. Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell. 1993;75:843–54.

    Article  CAS  Google Scholar 

  10. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer. 2006;6:857–66.

    Article  CAS  Google Scholar 

  11. Shen H, Wang L, Ge X, Jiang C, Shi Z. MicroRNA-137 inhibits tumor growth and sensitizes chemosensitivity to paclitaxel and cisplatin in lung cancer. Oncotarget. 2016;7:1–15.

    Google Scholar 

  12. Gao W, Lu X, Liu L, Xu J, Feng D, Shu Y. MiRNA-21. A biomarker predictive for platinum-based adjuvant chemotherapy response in patients with non-small cell lung cancer. Cancer Biol Ther. 2012;13:330–40.

    Article  CAS  Google Scholar 

  13. Robertson KD. DNA methylation, methyltransferases, and cancer. Oncogene. 2001;20:3139–55.

    Article  CAS  Google Scholar 

  14. Hervouet E, Cheray M, Vallette F, Cartron P-F. DNA methylation and apoptosis resistance in cancer cells. Cells. 2013;2:545–73.

    Article  CAS  Google Scholar 

  15. Brueckner B, Stresemann C, Kuner R, Mund C, Musch T, Meister M, et al. The human let-7a-3 locus contains an epigenetically regulated microRNA gene with oncogenic function. Cancer Res. 2007;67:1419–23.

    Article  CAS  Google Scholar 

  16. Fabbri M, Garzon R, Cimmino A, Liu Z, Zanesi N, Callegari E, et al. MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B. Proc Natl Acad Sci USA. 2007;104:15805–10.

    Article  CAS  Google Scholar 

  17. Saito M, Shiraishi K, Matsumoto K, Schetter AJ, Ogata-Kawata H, Tsuchiya N, et al. A three-microRNA signature predicts responses to platinum-based doublet chemotherapy in patients with lung adenocarcinoma. Clin Cancer Res. 2014;20:4784–93.

    Article  CAS  Google Scholar 

  18. Eisenhauer Ea, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–47.

    Article  CAS  Google Scholar 

  19. Voortman J, Goto A, Mendiboure J, Sohn JJ, Aaron J, Saito M, et al. MicroRNA expression and clinical outcomes in patients treated with adjuvant chemotherapy after complete resection of non- small cell lung carcinoma. Cancer. 2011;70:8288–98.

    Google Scholar 

  20. Berghmans T, Ameye L, Willems L, Paesmans M, Mascaux C, Lafitte JJ, et al. Identification of microRNA-based signatures for response and survival for non-small cell lung cancer treated with cisplatin-vinorelbine A ELCWP prospective study. Lung Cancer. 2013;82:340–5.

    Article  CAS  Google Scholar 

  21. Berghmans T, Ameye L, Lafitte J-J, Colinet B, Cortot A, CsToth I, et al. Prospective validation obtained in a similar group of patients and with similar high throughput biological tests failed to confirm signatures for prediction of response to chemotherapy and survival in advanced NSCLC: a prospective study from the European. Front Oncol. 2015;4:386.

    Article  Google Scholar 

  22. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Ser B. 1995;289–300.

  23. Hou L-K, Ma Y-S, Han Y, Lu G-X, Luo P, Chang Z-Y, et al. Association of microRNA-33a molecular signature with non-small cell lung cancer diagnosis and prognosis after chemotherapy. PLoS ONE. 2017;12:e0170431.

    Article  Google Scholar 

  24. Dietrich D, Hasinger O, Liebenberg V, Field JK, Kristiansen G, Soltermann A. Methylation of the homeobox genes PITX2 and SHOX2 predicts outcome in non-small-cell lung cancer patients. Diagn Mol Pathol. 2012;21:93–104.

    Article  CAS  Google Scholar 

  25. Wu F, Lu M, Qu L, Li D-Q, Hu C-H. DNA methylation of hMLH1 correlates with the clinical response to cisplatin after a surgical resection in non-small cell lung cancer. Int J Clin Exp Pathol. 2015;8:5457–63.

    CAS  PubMed  PubMed Central  Google Scholar 

  26. De Fraipont F, Levallet G, Creveuil C, Bergot E, Beau-Faller M, Mounawar M, et al. An apoptosis methylation prognostic signature for early lung cancer in the IFCT-0002 trial. Clin Cancer Res. 2012;18:2976–86.

    Article  Google Scholar 

  27. Brodie SA, Lombardo C, Li G, Kowalski J, Gandhi K, You S, et al. Aberrant promoter methylation of Caveolin-1 is associated with favorable response to taxane-platinum combination chemotherapy in advanced NSCLC. PLoS ONE. 2014;9:e107124.

  28. Wei J, Gao W, Zhu CJ, Liu YQ, Mei Z, Cheng T, et al. Identification of plasma microRNA-21 as a biomarker for early detection and chemosensitivity of non-small cell lung cancer. Chin J Cancer. 2011;30:407–14.

    Article  CAS  Google Scholar 

  29. Wei J, Liu LK, Gao W, Zhu CJ, Liu YQ, Cheng T, et al. Reduction of plasma MicroRNA-21 is associated with chemotherapeutic response in patients with non-small cell lung cancer. Chin J Cancer Res. 2011;23:123–8.

    Article  CAS  Google Scholar 

  30. Li Z-H, Zhang H, Yang Z-G, Wen G-Q, Cui Y-B, Shao G-G. Prognostic significance of serum microRNA-210 levels in nonsmall-cell lung cancer. J Int Med Res. 2013;41:1437–44.

    Article  CAS  Google Scholar 

  31. Cui E, Li H, Hua F, Wang B, Mao W, Feng X, et al. Serum microRNA 125b as a diagnostic or prognostic biomarker for advanced NSCLC patients receiving cisplatin-based chemotherapy. Acta Pharmacol Sin. 2012;34:309–13.

    Article  Google Scholar 

  32. Wu C, Cao Y, He Z, He J, Hu C, Duan H, et al. Serum levels of miR-19b and miR-146a as prognostic biomarkers for non-small cell lung cancer. Tohoku J Exp Med. 2014;232:85–95.

    Article  CAS  Google Scholar 

  33. Zhu J, Qi Y, Wu J, Shi M, Feng J. Evaluation of plasma microRNA levels to predict insensitivity of patients with advanced lung adenocarcinomas to pemetrexed and platinum. Oncol Lett. 2016;12:4829–37.

    Article  CAS  Google Scholar 

  34. Wang F, Lou JF, Cao Y, Shi XH, Wang P, Xu J, Xie EF, Xu T, Sun RH, Rao JY, Huang PW, Pan SYWH. miR-638 is a new biomarker for outcome prediction of non-small cell lung cancer patients receiving chemotherapy. Exp Mol Med. 2015;47:e162.

    Article  CAS  Google Scholar 

  35. Ponomaryova AA, Morozkin ES, Rykova EY, Zaporozhchenko IA, Skvortsova TE, Dobrodeev Y, et al. Dynamic changes in circulating miRNA levels in response to antitumor therapy of lung cancer. Exp Lung Res. 2016;42:1–8.

    Article  Google Scholar 

  36. Lissa D, Robles AI. Methylation analyses in liquid biopsy. Transl Lung Cancer Res. 2016;5:492–504.

    Article  CAS  Google Scholar 

  37. Ramirez JL, Rosell R, Taron M, Sanchez-Ronco M, Alberola V, de las Peñas R, et al. 14-3-3σ Methylation in pretreatment serum circulating DNA of cisplatin-plus-gemcitabine-treated advanced non-small-cell lung cancer patients predicts survival: The Spanish Lung Cancer Group. J Clin Oncol. 2005;23:9105–12.

    Article  CAS  Google Scholar 

  38. Zhai X, Li S-J. Methylation of RASSF1A and CDH13 genes in individualized chemotherapy for patients with non-small cell lung cancer. Asian Pac J Cancer Prev. 2014;15:4925–8.

    Article  Google Scholar 

  39. Ponomaryova AA, Rykova EY, Cherdyntseva NV, Skvortsova TE, Dobrodeev AY, Zav’yalov AA, et al. Potentialities of aberrantly methylated circulating DNA for diagnostics and post-treatment follow-up of lung cancer patients. Lung Cancer. 2013;81:397–403.

    Article  Google Scholar 

  40. Schmidt B, Beyer J, Dietrich D, Bork I, Liebenberg V, Fleischhacker M. Quantification of cell-free mSHOX2 plasma DNA for therapy monitoring in advanced stage non-small cell (NSCLC) and small-cell lung cancer (SCLC) patients. PLoS ONE. 2015;10:1–10.

    CAS  Google Scholar 

  41. Wang H, Zhang B, Chen D, Xia W, Zhang J, Wang F, et al. Real-time monitoring efficiency and toxicity of chemotherapy in patients with advanced lung cancer. Clin Epigenetics Clin Epigenetics. 2015;7:119.

    Article  Google Scholar 

  42. Liu Z-L, Wang H, Liu J, Wang Z-X. MicroRNA-21 (miR-21) expression promotes growth, metastasis, and chemo- or radioresistance in non-small cell lung cancer cells by targeting PTEN. Mol Cell Biochem. 2013;372:35–45.

    Article  CAS  Google Scholar 

  43. Xu L, Huang Y, Chen D, He J, Zhu W, Zhang Y, et al. Downregulation of miR-21 increases cisplatin sensitivity of non-small-cell lung cancer. Cancer Genet. 2014;207:214–20.

    Article  CAS  Google Scholar 

  44. Dong Z, Ren L, Lin L, Li J, Huang Y, Li J. Effect of microRNA-21 on multidrug resistance reversal in A549/DDP human lung cancer cells. Mol Med Rep. 2015;11:682–90.

    Article  CAS  Google Scholar 

  45. Saito M, Schetter AJ, Mollerup S, Kohno T, Skaug V, Bowman ED, et al. The association of microRNA expression with prognosis and progression in early-stage, non-small cell lung adenocarcinoma: a retrospective analysis of three cohorts. Clin Cancer Res. 2011;17:1875–82.

    Article  CAS  Google Scholar 

  46. Markou A, Tsaroucha EG, Kaklamanis L, Fotinou M, Georgoulias V, Lianidou ES. Prognostic value of mature MicroRNA-21 and MicroRNA-205 overexpression in non-small cell lung cancer by quantitative real-time RT-PCR. Clin Chem. 2008;54:1696–704.

    Article  CAS  Google Scholar 

  47. Robles AI, Arai E, Mathé EA, Okayama H, Schetter AJ, Brown D, et al. An integrated prognostic classifier for stage I lung adenocarcinoma based on mRNA, microRNA, and DNA methylation biomarkers. J Thorac Oncol Int Assoc Study Lung Cancer. 2015;10:1037–48.

    CAS  Google Scholar 

  48. Zhu W, Xu B. MicroRNA-21 identified as predictor of cancer outcome: a meta-analysis. PLoS ONE. 2014;9:e103373.

    Article  Google Scholar 

  49. Seike M, Goto A, Okano T, Bowman ED, Schetter AJ, Horikawa I, et al. MiR-21 is an EGFR-regulated anti-apoptotic factor in lung cancer in never-smokers. Proc Natl Acad Sci. 2009;106:12085–90.

    Article  CAS  Google Scholar 

  50. Svoboda M, Sana J, Fabian P, Kocakova I, Gombosova J, Nekvindova J, et al. MicroRNA expression profile associated with response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer patients. Radiat Oncol Radiat Oncol. 2012;7:195.

    Article  CAS  Google Scholar 

  51. Ye L, Jiang T, Shao H, Zhong L, Wang Z, Liu Y, et al. miR-1290 is a novel biomarker in DNA mismatch repair–deficient colon cancer and promotes resistance to 5-fluorouracil by directly targeting hMSH2. Mol Ther Nucleic Acids. 2017;7:453–64.

    Article  CAS  Google Scholar 

  52. Zhou L, Qiu T, Xu J, Wang T, Wang J, Zhou X, et al. miR-135a/b modulate cisplatin resistance of human lung cancer cell line by targeting MCL1. Pathol Oncol Res. 2013;19:677–83.

    Article  CAS  Google Scholar 

  53. Kjersem JB, Ikdahl T, Lingjaerde OC, Guren T, Tveit KM, Kure EH. Plasma microRNAs predicting clinical outcome in metastatic colorectal cancer patients receiving first-line oxaliplatin-based treatment. Mol Oncol. 2014;8:59–67.

    Article  CAS  Google Scholar 

  54. Yang T, Chen T, Li Y, Gao L, Zhang S, Wang T, et al. Downregulation of miR-25 modulates non-small cell lung cancer cells by targeting CDC42. Tumor Biol. 2015;36:1903–11.

    Article  CAS  Google Scholar 

  55. Song J, Li Y. miR-25-3p reverses epithelial-mesenchymal transition via targeting Sema4C in cisplatin-resistance cervical cancer cells. Cancer Sci. 2017;108:23–31.

    Article  CAS  Google Scholar 

  56. Rasmussen MH, Jensen NF, Tarpgaard LS, Qvortrup C, Rømer MU, Stenvang J, et al. High expression of microRNA-625-3p is associated with poor response to first-line oxaliplatin based treatment of metastatic colorectal cancer. Mol Oncol. 2013;7:1–10.

    Article  Google Scholar 

  57. Jiang J, Lv X, Fan L, Huang G, Zhan Y, Wang M, et al. MicroRNA-27b suppresses growth and invasion of NSCLC cells by targeting Sp1. Tumor Biol. 2014;35:10019–23.

    Article  CAS  Google Scholar 

  58. Radhakrishnan VM, Jensen TJ, Cui H, Futscher BW, Martinez JD. Hypomethylation of the 14-3-3σ promoter leads to increased expression in non-small cell lung cancer. Genes Chromosom Cancer. 2011;50:830–6.

    Article  CAS  Google Scholar 

  59. Donninger H, Vos MD, Clark GJ. The RASSF1A tumor suppressor. J Cell Sci. 2007 ;120:3163 LP–3172.

    Article  Google Scholar 

  60. Donninger H, Clark J, Rinaldo F, Nelson N, Barnoud T, Schmidt ML, et al. The RASSF1A tumor suppressor regulates XPA-mediated DNA repair. Mol Cell Biol. 2015;35:277–87.

    Article  Google Scholar 

  61. Grawenda AM, O’Neill E. Clinical utility of RASSF1A methylation in human malignancies. Br J Cancer. 2015;113:372–81.

    Article  CAS  Google Scholar 

  62. Dubois F, Keller M, Calvayrac O, Soncin F, Hoa L, Hergovich A, et al. RASSF1A suppresses the invasion and metastatic potential of human non-small cell lung cancer cells by inhibiting YAP activation through the GEF-H1/RhoB pathway. Cancer Res. 2016;76:1627–40.

    Article  CAS  Google Scholar 

  63. Fischer JR, Ohnmacht U, Rieger N, Zemaitis M, Stoffregen C, Kostrzewa M, et al. Promoter methylation of RASSF1A, RARβ and DAPK predict poor prognosis of patients with malignant mesothelioma. Lung Cancer. 2006;54:109–16.

    Article  Google Scholar 

  64. Vetterkind S, Poythress RH, Lin QQ, Morgan KG. Hierarchical scaffolding of an ERK1/2 activation pathway. Cell Commun Signal. 2013;11:1.

    Article  Google Scholar 

  65. Bertino EM, Williams TM, Nana-Sinkam SP, Shilo K, Chatterjee M, Mo X, et al. Stromal caveolin-1 is associated with response and survival in a phase II trial of nab-Paclitaxel with carboplatin for advanced NSCLC patients. Clin Lung Cancer. 2015;16:466–74.

    Article  CAS  Google Scholar 

  66. Li J, Feng Q, Wei X, Yu Y. MicroRNA-490 regulates lung cancer metastasis by targeting poly r(C)-binding protein 1. Tumor Biol. 2016;37:15221–8.

    Article  CAS  Google Scholar 

  67. Blower PE, Chung JH, Verducci JS, Lin S, Park JK, Dai Z, et al. MicroRNAs modulate the chemosensitivity of tumor cells. Mol Cancer Ther. 2008;7:1–9.

    Article  CAS  Google Scholar 

  68. Galluzzi L, Morselli E, Vitale I, Kepp O, Senovilla L, Criollo A, et al. miR-181a and miR-630 regulate cisplatin-induced cancer cell death. Cancer Res. 2010;70:1793–803.

    Article  CAS  Google Scholar 

  69. Ceppi P, Mudduluru G, Kumarswamy R, Rapa I, Scagliotti GV, Papotti M, et al. Loss of miR-200c expression induces an aggressive, invasive, and chemoresistant phenotype in non-small cell lung cancer. Mol Cancer Res. 2010;8:1207–16.

    Article  CAS  Google Scholar 

  70. Kwon Y, Kim Y, Eom S, Kim M, Park D, Kim H, et al. MicroRNA-26a/-26b-COX-2-MIP-2 loop regulates allergic inflammation and allergic inflammation-promoted enhanced tumorigenic and metastatic potential of cancer cells. J Biol Chem. 2015;290:14245–66.

    Article  CAS  Google Scholar 

  71. Pérez-Ramírez C, Cañadas-Garre M, Robles AI, Molina MÁ, Faus-Dáder MJ, Calleja-Hernández MÁ. Liquid biopsy in early stage lung cancer. Transl Lung Cancer Res. 2016;5:517–24.

    Article  Google Scholar 

  72. Igaz I, Igaz P. Tumor surveillance by circulating microRNAs: a hypothesis. Cell Mol Life Sci. 2014;71:4081–7.

    Article  CAS  Google Scholar 

  73. Chevillet JR, Lee I, Briggs HA, He Y, Wang K. Issues and prospects of microRNA-based biomarkers in blood and other body fluids. Molecules. 2014;19:6080–105.

    Article  Google Scholar 

  74. Tiberio P, Callari M, Angeloni V, Daidone MG, Appierto V Challenges in using circulating miRNAs as cancer biomarkers. Biomed Res Int. 2015;2015:731479. https://doi.org/10.1155/2015/731479

  75. Van Pottelberge GR,Mestdagh P,Bracke KR,Thas O,Van Durme YMTA, Joos GF, et al. Van Durme YMTA, Joos GF, et al. MicroRNA expression in induced sputum of smokers and patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2011;183:898–906.

    Article  Google Scholar 

  76. Takahashi K, Yokota S, Tatsumi N, Fukami T, Yokoi T, Nakajima M. Cigarette smoking substantially alters plasma microRNA profiles in healthy subjects. Toxicol Appl Pharmacol. 2013;272:154–60.

    Article  CAS  Google Scholar 

Download references

Author contributions

Conception and design: WMS, ODR, AIR, TM, UGIF. Administrative support: WMS. Provision of study materials or patients: WMS. Collection and assembly of data: WMS. Data analysis and interpretation: WMS, ODR, AIR, TM, UGIF. Manuscript writing: All authors. Final approval of manuscript: All authors.

Funding

AIR is supported by the Intramural Research Program of the National Cancer Institute, NIH.

Author information

Authors and Affiliations

  1. Department of Oncology, Aalborg University Hospital, Hobrovej 18-22, 9000, Aalborg, Denmark

    Weronika Maria Szejniuk, Tine McCulloch, Ursula Gerda Inge Falkmer & Oluf Dimitri Røe

  2. Clinical Cancer Research Center, Aalborg University Hospital, Hobrovej 18-22, 9000, Aalborg, Denmark

    Weronika Maria Szejniuk, Ursula Gerda Inge Falkmer & Oluf Dimitri Røe

  3. Laboratory of Human Carcinogenesis, National Cancer Institute, Center for Cancer Research, National Institutes of Health, Bethesda, MD, 20892, USA

    Ana I. Robles

  4. Cancer Clinic, Levanger Hospital, Nord-Trøndelag Health Trust, Levanger, Norway

    Oluf Dimitri Røe

  5. Department of Clinical Cancer Research and Molecular Medicine, Norwegian University of Science and Technology (NTNU), Trondheim, Norway

    Oluf Dimitri Røe

Authors
  1. Weronika Maria Szejniuk
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ana I. Robles
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Tine McCulloch
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ursula Gerda Inge Falkmer
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Oluf Dimitri Røe
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Weronika Maria Szejniuk.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Szejniuk, W.M., Robles, A.I., McCulloch, T. et al. Epigenetic predictive biomarkers for response or outcome to platinum-based chemotherapy in non-small cell lung cancer, current state-of-art. Pharmacogenomics J 19, 5–14 (2019). https://doi.org/10.1038/s41397-018-0029-1

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41397-018-0029-1

This article is cited by

Search

Advanced search

Quick links